Cancers, Vol. 11, Pages 577: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts
Cancers, Vol. 11, Pages 577: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts
Cancers doi: 10.3390/cancers11040577
Authors:
Holly A. Maulhardt
Lauren Hylle
Michael V. Frost
Ashley Tornio
Sara Dafoe
Leanne Drummond
David I. Quinn
Ashish M. Kamat
Gere S. diZerega
Intratumoral (IT) administration of submicron particle docetaxel (NanoDoce®, NanOlogy LLC, Fort Worth, TX, USA) and its efficacy against genitourinary-oncologic xenografts in rats and mice, xenograft-site docetaxel concentrations and immune-cell infiltration were studied. IT-NanoDoce®, IV-docetaxel and IT-vehicle were administered to clear cell renal carcinoma (786-O: rats), transitional cell bladder carcinoma (UM-UC-3: mice) and prostate carcinoma (PC-3: mice). Treatments were given every 7 days with 1, 2, or 3 doses administered. Animals were followed for tumor growth and clinical signs. At necropsy, 786-O and UM-UC-3 tumor-site tissues were evaluated by H&E and IHC and analyzed by LC-MS/MS for docetaxel concentration. Two and 3 cycles of IT-NanoDoce® significantly reduced UM-UC-3 tumor volume (p < 0.01) and eliminated most UM-UC-3 and 786-O tumors. In both models, NanoDoce® treatment was associated with (peri)tumor-infiltrating immune cells. Lymphoid structures were observed in IT-NanoDoce®-tre...
Source: Cancers - Category: Cancer & Oncology Authors: Holly A. Maulhardt Lauren Hylle Michael V. Frost Ashley Tornio Sara Dafoe Leanne Drummond David I. Quinn Ashish M. Kamat Gere S. diZerega Tags: Article Source Type: research
More News: Allergy & Immunology | Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Docetaxel | Nanotechnology | Prostate Cancer | Study | Taxotere | Toxicology | Transitional Cell Carcinoma